use of katphaladi churna in tamaka shwasa w.s.r. to bronchial asthama

Phase 3

• Conditions: Health Condition 1: J041- Acute tracheitis

• Registration Number: CTRI/2022/04/041707
• Lead Sponsor: Dr Sarita Kumari

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 2 May 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Intermittent and mild persistent cases of asthma.

1. Symptoms/exacerbation (wheeze, cough and breathlessness) 2 days/week but not daily.

2. Night time awakening 4 times/month.

3. Asthmatics who meet reversibility criteria [15% improvement in PEFR value after bet a-2

agonist inhalation ( Salbutamol - 2 puff)].

4. Symptoms according to Charak Samhita Adhyay 17/56-62 (4 essential + any >=2 other

symptoms mention bellow)

Exclusion Criteria

Age below 18 year and above 60 year.

2. Moderate persistent, severe persistent asthma.

3. Dyspnoea due to other disease like- LVF, COPD, Upper respiratory tract obstruction,

Bronchiectasis, Tuberculosis, Interstitial lung disease, Tropical pulmonary eosinophilia

etc.

4. Uncontrolled diabetes mellitus, hypertension and any other systemic disorders.

5. Pregnant or lactating mother

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
objective parameters: PEFR, Eosinophils count, spirometry, Total lung capacity before and after treatmentTimepoint: 2 months

Secondary Outcome Measures

Name	Time	Method
shows improvement in objective parameters such as PEFR, Eosinophils count, spirometry, Total lung capacity after treatmentTimepoint: 15 days